Aurobindo Pharma today reported consolidated net profit of Rs 108.6 crore for the fourth quarter ended March 31 2013, almost same as in the year-ago period.
Its net profit in the January-March quarter of FY12 was Rs 108 crore, Aurobindo Pharma said in a filing to BSE.
The consolidated total income from operations of the company in Q4 went up to Rs 1,570 crore, over Rs 1,190 crore in the year-ago period of FY 2011-12, the statement added.
The company’s Managing Director, N Govindarajan said, “Leveraging on steady flow of product approvals and traction in the existing basket across key markets has helped better capacity utilisation thereby improving revenues and bottomline on a year-on-year basis.”
Aurobindo expects the growth momentum to continue through new product launches and unfolding of our injectable portfolio, he said, adding that it hopes to deliver on better operational performance in the coming quarters with improved business mix both in formulations and APIs.
Aurobindo Pharma’s standalone net profit for the quarter ended March 31, 2013 went up to Rs 163 crore, over Rs 87 crore in the same period of the FY12, the statement added.
The company scrip closed at Rs 177.40 on the BSE, up 0.48 per cent, from the previous close.